Conferences

NOCITA® (bupivacaine liposome injectable suspension) will be featured at the Aratana booth during these upcoming conferences:

IVECCS 2018

At IVECCS, held this year in New Orleans, Aratana will host a breakfast session (6:30 - 7:30 a.m.) on Monday, September 17, featuring Andrea Looney DVM, DACVAA, DACVSMR. Dr. Looney will present on the use of local anesthetics and showcase a few examples of how she has successfully incorporated NOCITA into her canine CCL practice protocols during a time when so few analgesics are available.

 

Aratana will also hold a NOCITA lunch session for Veterinary Technicians (12:00 - 1:00 p.m.) on Sunday, September 16. Stephen Cital, RVT, SRA, RLAT, VCCS, VTS-LAM (Res. Anesthesia) will present how NOCITA has helped take control of the post-operative recovery period in his place of practice.

IVECCS Conference Link >

Veterinary Anesthesia Nerds Symposium 2018

As a key sponsor, Aratana will feature NOCITA as the only long-acting local anesthetic that controls post-operative pain with one dose at the source for up to 72 hours following canine CCL surgery or feline onychectomy to help patients recover comfortably while minimizing the risk of systemic analgesics.

The Veterinary Anesthesia Nerds (VAN) symposium provides two days of in-depth continuing education seminars led by world-class instructors at the Oqeundo Center in Las Vegas, October 8-9, 2018.

VAN Conference Link >

VCS 2018

Aratana will continue to showcase NOCITA in Louisville, Ky. Aratana plans to host a breakfast session for Veterinary Technicians (6:30 - 7:30 a.m.) on Friday, October 19 with Stephen Cital, RVT, SRA, RLAT, VCCS, VTS-LAM (Res. Anesthesia) presenting how NOCITA has helped take control of the post-operative recovery period in his place of practice.

VCS Conference Link >

ACVS 2018

At ACVS in Phoenix, Aratana will continue to showcase NOCITA, which was recently FDA-approved for use as a peripheral nerve block to provide up to 72 hours of regional post-operative analgesia following onychectomy in cats. Aratana will present the safety and efficacy data for use of NOCITA in cats at a lunch session (12:15 - 1:15 p.m.) on Friday, October 26.

ACVS Conference Link >

Now Approved For Cats

NOCITA is now FDA-approved for use in cats as a peripheral nerve block to provide regional post-operative analgesia following onychectomy. Please see the full Prescribing Information for more detail.

DOG INDICATION: For single-dose infiltration into the surgical site to provide local post-operative analgesia for cranial cruciate ligament surgery in dogs.

IMPORTANT SAFETY INFORMATION: NOCITA® (bupivacaine liposome injectable suspension) is for local infiltration injection in dogs only. Do not use in dogs younger than 5 months of age, that are pregnant, lactating or intended for breeding. Do not administer by intravenous or intra‐arterial injection. Adverse reactions in dogs may include discharge from incision, incisional inflammation and vomiting. Avoid concurrent use with bupivacaine HCl, lidocaine or other amide local anesthetics. Please see the full Prescribing Information for more detail.

CAT INDICATION: For use as a peripheral nerve block to provide regional post-operative analgesia following onychectomy in cats.

IMPORTANT SAFETY INFORMATION: NOCITA® (bupivacaine liposome injectable suspension) is for use as a peripheral nerve block in cats only. Do not use in cats younger than 5 months of age, that are pregnant, lactating, or intended for breeding. Do not administer by intravenous or intra‐arterial injection. Adverse reactions in cats may include elevated body temperature, infection or chewing/licking at the surgical site. Avoid concurrent use with bupivacaine HCl, lidocaine or other amide local anesthetics. Please see the full Prescribing Information for more detail.

Other therapeutics from Aratana

ENTYCE logo

Finally, appetite stimulation is in your control.

ENTYCE® (capromorelin oral solution) is the ONLY FDA-approved veterinary therapeutic designed to safely and effectively stimulate appetite in dogs. Administered orally once a day, ENTYCE is appropriate for treating inappetence caused by chronic and acute conditions.

VIEW WEBSITE

IMPORTANT SAFETY INFORMATION: ENTYCE® (capromorelin oral solution) is for use in dogs only. Do not use in breeding, pregnant or lactating dogs. Use with caution in dogs with hepatic dysfunction or renal insufficiency. Adverse reactions in dogs may include diarrhea, vomiting, polydipsia, and hypersalivation. Should not be used in dogs that have a hypersensitivity to capromorelin. Please see the full Prescribing Information for more detail.